Webinar on Predicting VHH-Fc Developability with IgG Data
The upcoming webinar hosted by Xtalks, titled
Preventing VHH-Fc Developability from Large-Scale IgG Data, promises to be an enlightening session for professionals in the biotech and pharmaceutical fields. Scheduled for
December 9, 2026, at 12 PM EST, this free event will feature
Josh Moller, a Senior Engineer from Ginkgo Datapoints, who will delve into the intricacies of predictive modeling using antibody data.
In the pharmaceutical industry, understanding whether a therapeutic protein can be effectively manufactured and formulated is critical. Traditionally, this calls for extensive experimental campaigns focusing on each molecular format. However, the webinar will present a compelling case for leveraging existing datasets from IgG antibodies to enhance VHH-Fc developability assessments. This innovative approach not only saves time and resources but also redefines how antibody development decisions are made.
The Importance of Predictive Modeling
During the session, attendees will gain insights into how predictive models built on conventional IgG antibody data can be aptly applied to evaluate the developability of VHH-Fc constructs. The session will feature findings from a significant dataset of VHH-Fc, which comprises data from over
160 members across ten standardized biophysical assays. It will also explore whether models solely trained on
559 IgGs can successfully predict the developability properties of scaffolds that do not contain essential elements such as a light chain or a CH1 domain.
A key highlight will be comparing predictive power: do insights derived from 559 examples of a different antibody format provide better predictive capabilities than smaller sets from the target format? Webinar participants can expect real data points and results showcasing the accuracy of predictions across various biophysical properties.
Exploring Cross-Format Predictions
The webinar will particularly address how the model's accuracy fluctuates across various biophysical properties such as heparin binding, hydrophobicity, self-association, thermostability, and more. Remarkably, findings reveal that while certain properties show high transferability—such as heparin binding with a Spearman correlation of 0.82 and hydrophobicity at 0.63—others, like thermostability, yield lower predictive success, highlighting differences in interdomain behaviors across formats.
The choice of modeling architecture will also be discussed. The session will clarify that tabular neural networks often outperform linear and tree-based models when adapting to cross-format differences, thus emphasizing the importance of selecting the right model for predictive success.
Registration and Expectations
For anyone keen on understanding how IgG datasets can be utilized for assessing VHH-Fc developability, this webinar is unmissable. Register to learn from real-world applications and discover how predictive modeling can revolutionize decision-making in antibody development.
As professionals in the life sciences sector strive to stay ahead, resources like these provided by Xtalks play an essential role in keeping the community connected and informed. Explore insights signed from Ginkgo's extensive research and learn how predictive modeling can enhance your methodologies in therapeutic protein development.
To register for this insightful event, please visit the Xtalks website or the link provided:
Predicting VHH-Fc Developability from Large-Scale IgG Data for more details.
About Xtalks
Xtalks is a trusted resource delivering knowledge across the pharma, biotech, medtech, and healthcare sectors. By providing news, webinars, and expert perspectives, they empower professionals to make informed decisions in a rapidly evolving industry. With thousands relying on Xtalks each year, participating in their programs ensures you remain engaged and informed about the latest trends and advancements in life sciences.
For more information, or if you're interested in hosting your own webinar with Xtalks, visit
Xtalks Partner with Us.